ClinicalTrials.gg
CompletedNCT04175171Updated Dec 18, 2019

Clinical Trial of Comparative Study of GB221 Pharmacokinetics

A Phase 1 interventional study of Coprelotamab Injection and Trastuzumab Injection in Metastatic Breast Cancer, sponsored by Genor Biopharma Co., Ltd.. Completed at 1 site in Australia. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-18.

Sponsored by Genor Biopharma Co., Ltd. (part of Edding Genor Group Holdings Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 8 years after the study started (first participant enrolled Nov 2011, registered Nov 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 402 studies in Breast Neoplasms with a site in Australia — 84 open to participants now, 156 under way, 61 of them phase 3. Breast Neoplasms · Australia.

Enrollment
344th of 380
32 · median 253
Started
2011
with 7 others
Phase 1
72 of 402
23 open now
Registered
241st of 402
by date

Among the 402 studies in Breast Neoplasms with a site in Australia, this one is the 344th largest by enrollment of the 380 interventional ones that give a count, is one of 8 that started in 2011, is one of 72 in phase 1, and was the 241st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

84 of the 402 studies in Breast Neoplasms with a site in Australia are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 402 studies in Breast Neoplasms with a site in Australia, or all of them as a file.
02

Study summary

The primary objective is to assess the safety of a single dose of GB221 compared to Herceptin® when administered as a single IV injection at a dose of 8 mg/kg. The secondary objective of the study is to assess the pharmacokinetics of GB221 compared to Herceptin®.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be enrolled in the study, subjects must meet the following criteria

  1. Males aged 18 to 45 years.
  2. Healthy as judged by medical examination and medical history, and clinical chemistry and hematology screening.
  3. Body weight within the normal range for height ( between 19.0 and 29.0, inclusive) up to a maximum of 90 kg.
  4. Normal or non- .
  5. Normotensive (systolic: 90 - 140; diastolic: 50 - 90 mm Hg, inclusive) and heart rate (40 -100 bpm, inclusive).
  6. Willingness to give written and prior to any studyrelated procedures being conducted

Exclusion criteria

Exclusion Criteria:

Subjects will be ineligible for the study if any of the following criteria apply:

  1. Receipt of any agent or drug within 4 weeks of entry to the study.
  2. Use of any medicine - prescription, over-the-counter or herbal - in the 7 days prior to the treatment day and until 12 weeks after the treatment day.
  3. Donation of blood (or loss of blood) greater than 400 ml within 3 months of the study.
  4. drug allergy or sensitivity to any medication.
  5. A history of chronic or recurrent infections.
  6. A recent history of surgery.
  7. History or presence of (with the exception of successfully treated basal cell carcinoma).
  8. Inability to communicate or cooperate with the Principal Investigator because of English language difficulties or poor mental development.
  9. A history (within the last 5 years) or evidence of alcohol or drug abuse (excepting tobacco use less than 10 cigarettes per day).
  10. A positive urine test for drugs of abuse or alcohol either at screening or on the day of admittance for drug administration.
  11. Vaccination of any type within the previous month.
  12. A history of major psychiatric illness (such as bipolar disorder, schizophrenia or persistent major depression). Previous minor depression/adjustment disorder is acceptable if currently asymptomatic.
  13. Consumption of more than 3 standard drinks per day, and not able to abstain from alcohol totally within 24 hours of dose administration.
  14. Presence of current infection with tuberculosis, , or .
  15. History of asthma or other chronic respiratory disease in the past 5 years.
  16. History of neurological or neuromuscular disease.
  17. History of hypertension or cardiovascular disease, including congestive heart failure and cardiomyopathy or a clinically significant echocardiogram finding at the screening visit.
  18. History of bladder or urethral disease.
  19. Smoking cigarettes > 10 per day.
  20. Any other condition which in the view of the Principal Investigator is likely to interfere with the study or put the subject at risk.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    GB221

    Coprelotamab Injection, 8mg/kg, single dose

    Drug: Coprelotamab Injection

  • Active comparator
    Herceptin

    Trastuzumab Injection, 8mg/kg, single dose

    Drug: Trastuzumab Injection

Interventions

  • DrugCoprelotamab Injection

    The single intravenous infusion of 8mg/kg Coprelotamab shall be administered within 90 minutes through infusion pump.

    Also known as: GB221

  • The single intravenous infusion of 8mg/kgTrastuzumab shall be administered within 90 minutes through infusion pump.

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. physical examination

    physical examination

    Time frame: Up to 84 days

  2. adverse event

    adverse event

    Time frame: Up to 84 days

  3. blood pressure

    blood pressure

    Time frame: Up to 84 days

  4. heart rate

    heart rate

    Time frame: Up to 84 days

  5. respiration rate

    respiration rate

    Time frame: Up to 84 days

  6. oxygen saturation

    oxygen saturation

    Time frame: Up to 84 days

  7. temperature

    temperature

    Time frame: Up to 84 days

Secondary outcomes

  1. C max

    C max

    Time frame: Up to 84 days

  2. t max

    t max

    Time frame: Up to 84 days

  3. AUC

    AUC

    Time frame: Up to 84 days

  4. CL

    CL

    Time frame: Up to 84 days

  5. t ½

    t ½

    Time frame: Up to 84 days

  6. V

    V

    Time frame: Up to 84 days

07

Study locations

1 site
  • Linear Clinical Research Limited
    Nedlands, Western Australia 6009, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2011 to primary completion in Jan 2012, 2 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 2 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2019
First posted
Nov 22, 2019
StartActual
Nov 7, 2011
Primary completionActual
Jan 8, 2012
CompletionActual
Mar 8, 2012
Last update
Dec 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04175171
Responsible party
Sponsor
First posted
Nov 22, 2019
Start date
Nov 7, 2011
Primary completion
Jan 8, 2012
Completion
Mar 8, 2012
Last update
Dec 18, 2019

Study contacts

Andrewn Redfer, PhD; MBBS
principal investigator · Linear Clinical Research Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion